Considering current developments in Alzheimer’s drugs, a US expert has predicted that the industry should “be prepared for more complex biological therapies that require intravenous infusion and vigilant monitoring for side effects; more like cancer therapies,” according to Dr Jeffrey Cummings, Alzheimer’s clinician-scientist and research professor at the School of Integrated Health Sciences, University of Nevada, Las Vegas.

Las Vegas loves its sports teams. The WNBA’s Aces arrived from San Antonio, Texas. We welcomed the Raiders, and soon-to-be Las Vegas A’s from Oakland. But the Vegas Golden Knights are Vegas-born, and their birth certificate was forged in our community’s darkest hours.

The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. On the heels of newly FDA-approved drugs Aduhelm (aducanumab) in 2021 and Leqembi (lecanemab) in 2023, a UNLV researcher says that 2024 is a "learning year" for Alzheimer's drug development.

Picture this: It's about 20 minutes after takeoff, and you hear your captain make an announcement. "Ladies and gentlemen, we've reached our cruising altitude of 35,000 feet," they say. Or, maybe they say 36,000 feet, or 40,000 feet, or 33,000 feet. Cruising altitude isn't actually a fixed number — there are many factors that go into computing this for every flight.

UNLV research shows a decline from the pandemic surge of Californians moving to Nevada.

Las Vegas’ history is filled with infamous stories of mobsters leaving their mark on the city throughout the years, and of course, they also need places to live while in Sin City.

At the end of 2023, astronomers made a startling discovery in the Orion Nebula. Using the James Webb Space Telescope (JWST), the team found 40 pairs of planetary mass objects — none of which orbit a star. They're called Jupiter-Mass Binary Objects, or JuMBOs.

The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a “learning year” for Alzheimer’s drug development.

An endowment of $1.05 million will fund career development for women in sports, according to a Wednesday news release from the UNLV Athletics Department. The Diana Bennett Career Development Program for Women’s Sports will provide internship programming, resume building, career professional development and a variety of networking and job experience initiatives. The program is part of the “Rebel Up” Campaign, the Athletics Department said.